@EddyG brought up the possibility of Bisantrene for weight loss a while ago.
The big question here is, is it causation or correlation between FTO, obesity and cancer?
If you're still in lock down and have time on your hands to read a few articles try looking into the different types of FTO variants. Then look at the genetic tests completed to see where people have more of the FTO genes and how this impacts them. There is then the relationship between FTO and obesity - ie, does certain FTO variants cause the obesity, or does it cause the hunger creating the obesity? Then the relationship between FTO and cancer - ie does the FTO variant increase the chances of cancer, or increase the likelihood of obesity that then increases likelihood of cancer?
My understanding is that Bisantrene is an inhibitor of the FTO protein which will help target and kill cancer cells, however it won't reduce the FTO protein (ie, won't reduce reduce hunger). Happy to be corrected on this though..
Also interesting looking into the impact fasting can have on cancer treatments. I believe this is due to the state it puts the body in prior to treatment stressing the healthy cells to fight and the cancer cells to be more exposed to the treatment. This again can be related back to the FTO (hunger) protein in my opinion.
Here are a few links I have read over in the past and just quickly dug up then (I can't remember what side of the ledger they are all on, but it's good to get a balanced view):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906751/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635949/#:~:text=Background,FTO%20genetic%20predisposition%20is%20unknown.
https://www.oncotarget.com/article/16446/text/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530042/
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO (new thread)
Pillar 1 - FTO (new thread), page-34
-
- There are more pages in this discussion • 2,988 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M |
Open | High | Low | Value | Volume |
$1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 807 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.69 | 2376 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 807 | 1.630 |
1 | 4000 | 1.600 |
2 | 2300 | 1.580 |
1 | 636 | 1.570 |
1 | 6000 | 1.560 |
Price($) | Vol. | No. |
---|---|---|
1.690 | 2376 | 1 |
1.735 | 3313 | 1 |
1.750 | 2000 | 1 |
1.790 | 1000 | 1 |
1.800 | 2000 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
RAC (ASX) Chart |